kaziatherapeutics.com (KZIA) - Gross Profit Margin

Official company branding of Kazia Therapeutics (KZIA)

Kazia Therapeutics (KZIA) is actively developing glioblastoma treatments that cross the blood-brain barrier. The gross profit margin clearly demonstrates the evolution of production yield, where 0.00 serves as the final level marker. The specifics of neuro-oncology render the business independent of economic cycles. Meanwhile, the company strictly adheres to clinical trial ethics and environmental standards regarding the disposal of laboratory waste.

KZIA (kaziatherapeutics.com) Return on Gross Profit history from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for kaziatherapeutics.com (KZIA)

- market price and analyst price targets:
Basic company analysis:Kazia Therapeutics (KZIA)
Manufactured products of Kazia Therapeutics

Gross margin measures production efficiency by determining the portion of revenue remaining after direct product costs. By analyzing gross profit margins, an investor identifies critical points between operational profitability and regulatory expenses, where the current value stands at 0.00. For Kazia Therapeutics (KZIA), this indicator reflects the financial pressure of costly overseas oncology trials and a reliance on external capital.